Empagliflozin for heart failure with preserved ejection fraction: targeting cardiac endothelial cell-cardiomyocyte interaction. (July 2018) - Juni, R.; Kuster, D.W.D.; Goebel, M.; Helmes, M.; van der Velden, J.; Musters, R.; Koolwijk, P.; Paulus, W.; van Hinsbergh, V.